Original Investigation

Fluid eMTBR-tau243 as a Biomarker of Mixed 3-Repeat and 4-Repeat Tau Pathology

JAMA 10.1001/jama.2026.24689

November 13, 2026 at 11:00 PM EST

Read the full article

Is an emerging fluid Alzheimer disease (AD) biomarker, endogenously cleaved form of tau microtubule binding region containing the residue 243 (eMTBR-tau243), elevated in other tau-related causes of dementia? In this case-control study of 229 participants, approximately one-half of whom had antemortem cerebrospinal fluid (CSF) and/or plasma paired with autopsy or genetically-defined neuropathology, CSF and plasma eMTBR-tau243 were elevated not only among those with AD but also among those with other mixed 3-repeat and 4-repeat (3R/4R) tauopathies including late-stage chronic traumatic encephalopathy (CTE) and symptomatic frontotemporal lobar degeneration with MAPT variants compared with cognitively unimpaired controls. The findings suggest that fluid eMTBR-tau243 specifically reflects symptomatic or late-stage mixed 3R/4R tau pathology, but further validation in larger cohorts is needed to understand whether eMTBR-tau243 has clinical utility as a potential diagnostic biomarker for CTE and other 3R/4R tauopathies beyond AD.

Meeting Information: This paper will be presented during the Japan Society for Dementia Research meeting.

Corresponding Authors: Kanta Horie, PhD (horiekanta@wustl.edu), and Chihiro Sato, PhD (satochihiro@wustl.edu), Department of Neurology, Washington University School of Medicine, 4370 Duncan Ave Neuroscience Research Building, St Louis, MO 63110.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.24689

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks